Sale of Zohydro ER business (Tables)

12 Months Ended

Dec. 31, 2016

Zohydro ER [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Net Assets and Calculation of the Gain on Sale

The following table summarizes the results of discontinued operations presented in the consolidated statements of operations for the periods indicated (in thousands):

	Year Ended December 31,
Discontinued operations	2016			2015			2014
Net product revenue	$	532		$	11,299		$	11,584
Operating expense (income):
Cost of product sold	15			2,205			10,554
Royalty expense	32			835			1,127
Research and development	—			5,504			7,043
Selling, general and administrative	1,594			14,820			54,260
Restructuring expense	—			588			—
Gain on sale of business	—			(89,484		)	—
Total operating expense (income)	1,641			(65,532		)	72,984
Other income	—			5,077			8,500
Net (loss) income from discontinued operations before tax	(1,109		)	81,908			(52,900		)
Tax benefit (expense)	88			(14,060		)	—
Net loss (income) from discontinued operations	$	(1,021	)	$	67,848		$	(52,900	)

Other income of $5.0 million in 2015 was attributed to payment received for the Company’s waiver of its regulatory exclusivity rights. Other income in 2014 was comprised of $3.5 million for the sale of right of reference to certain carcinogenicity data generated by the Company and a $5.0 million payment received for the Company’s waiver of its regulatory exclusivity rights.

The following table summarizes the assets and liabilities of discontinued operations as of December 31, 2016 and 2015 related to the Zohydro ER business (in thousands):

	December 31,
	2016		2015
Assets
Current assets
Trade accounts receivable	$	—	$	4
Inventory	—		15
Prepaid expenses and other current assets	—		189
Total current assets of discontinued operations	$	—	$	208
Liabilities
Current liabilities
Accrued expenses	414		2,796
Deferred revenue	—		110
Total current liabilities of discontinued operations	$	414	$	2,906